Form 4: Cormorant Asset Management Sells Shares of Immuneering Corp (IMRX)

Cormorant Asset Management, along with related entities, sold shares of Immuneering Corp (IMRX) in a series of open market transactions on March 14 and 15, 2024.

Summary

• Cormorant Asset Management, LP, along with related entities including Cormorant Global Healthcare Master Fund, LP and Cormorant Private Healthcare Fund III, LP, filed a Form 4 detailing changes in beneficial ownership of Immuneering Corp (IMRX) stock.
• The transactions involved the sale of Class A Common Stock on March 14 and 15, 2024.
• The sales occurred in multiple transactions at varying prices, ranging from $2.90 to $6.18 on March 14 and $1.90 to $2.82 on March 15.
• On March 14, 345,266 shares were sold at an average price of $3.235, 98,570 shares were sold at an average price of $4.245, 54,215 shares were sold at an average price of $5.374 and 11,040 shares were sold at an average price of $5.968.
• On March 15, 400,000 shares were sold at an average price of $2.141.
• Following these transactions, Cormorant's indirect beneficial ownership decreased, with remaining holdings split between the Master Fund and Fund III.
• After the transactions on March 15, the Master Fund beneficially owned 1,087,688 shares and Fund III beneficially owned 2,207,585 shares.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the filing itself is a standard procedure, the sale of shares by a major holder like Cormorant could create some uncertainty among investors.

Negatives

• Cormorant Asset Management reduced its stake in Immuneering Corp through open market sales, which could be interpreted negatively by the market.

Risks

• Continued selling pressure from Cormorant or other large shareholders could negatively impact IMRX's stock price.
• The reasons for Cormorant's sale of shares are not disclosed, creating uncertainty for investors.

Industry Context

Form 4 filings are a routine part of the US stock market and are required when company insiders or major shareholders trade the company's stock. This filing indicates a change in Cormorant Asset Management's position in Immuneering Corp.

Stakeholder Impact

• Shareholders may react to the news of Cormorant's share sales, potentially impacting the stock price.
• The impact on employees, customers, suppliers, and creditors is likely minimal unless the share sales signal a larger strategic shift.

Key Dates